

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
November 2, 2022
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 2, 2022.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Divya Ahuja, MD
Kimberly Rudd, MD
Kelly Barth, MD
Erika Tillery, PharmD

Edward Behling, MD
Jony Bolinger, MD
Kashyap Patel, MD
Patricia Witherspoon, MD

Duncan Norton, MD
Phillip Mubarak, MD
Kelli Savia, MD
Cheryl Hartvigsen, RPh

SC DHHS Staff:

Cheryl Anderson BS, RPh
Kimberly Bristow, RPh
Nicole Wetherton, JD
Ashley Sirianni, DNP, FNP-BC

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, August 3, 2022

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Janssen	Jonathan Jones, PharmD	Hafyera™ / Atypical Antipsychotics, Long Acting Injectables
Indivior	Dennis Sisson, PharmD	Perseris® / Atypical Antipsychotics, Long Acting Injectables
Alkermes	Timothy Birner, PharmD, MBA	Lybalvi® / 2 nd Generation Antipsychotics, Oral
AbbVie	John Dewitt, MD	Vraylar® / 2 nd Generation Antipsychotics, Oral
Intra-Cellular	Bradford Loo, PharmD	Caplyta® / 2 nd Generation Antipsychotics, Oral
AstraZeneca	Christine Dube, B.S., PharmD, PAHM	Brilinta® / Platelet Aggregation Inhibitors
Teva	Angela Bedenbaugh, PharmD	Austedo® / Movement Disorders

C. Drug Classes for Review

Classes for Re-Review

- Acne Agents, Topical
- Atypical Antipsychotics, Long Acting Injectables
- 2nd Generation Antipsychotics, Oral
- Platelet Aggregation Inhibitors

Classes for Review

- Movement Disorders

The chart below represents the recommendations from the P & T Committee:

ACNE AGENTS, TOPICAL	
Preferred	Non-Preferred
Azelex cream (azelaic acid 20%)	Clacosterone
Benzoyl peroxide OTC wash (5 and 10%)	Dapsone gel 7.5%
Benzoyl peroxide 6% cleanser – OTC	Differin® Gel cream, lotion/gel OTC
Benzoyl peroxide 5%/clindamycin phosphate 1.2% gel	Epiduo® Forte Gel
Clindamycin Phosphate	Finacea®
Differin® Gel pump*	Minocycline topical foam 4%
Erythromycin Soln/Swab	Salicylic acid/benzoyl peroxide
Retin A cream/gel	Sodium Sulfacetamide cream/gel/lotion
	Sodium sulfacetamide/sulfur
	Tazarotene
	Tretinoin
	Tretinoin 0.1%/benzoyl peroxide 3% cream

ACNE AGENTS, TOPICAL (continued)	
Preferred	Non-Preferred
	Clindamycin 1.2%/Tretinoin 0.025% gel
	Trifarotene cream 0.005%
ATYPICAL ANTIPSYCHOTICS, LONG ACTING INJECTABLES	
Preferred	Non-Preferred
Abilify Maintena®	Zyprexa® Relprevv™
Aristada® and Aristada® Initio	
Invega Sustenna®, Trinza®, Hafyera™ *	
Perseris®	
Risperdal Consta®	
2nd GENERATION ANTIPSYCHOTICS, ORAL	
Preferred	Non-Preferred
Aripiprazole	Brexpiprazole
Cariprazine*	Clozapine susp
Clozapine tabs/ODT	Iloperidone
Latuda®	Lumateperone
Olanzapine	Olanzapine/fluoxetine caps
Quetiapine IR and ER	Olanzapine/samidorphan
Risperidone	Paliperidone ER tabs
Saphris®	Pimavanserin
Ziprasidone caps	
PLATELET AGGREGATION INHIBITORS	
Preferred	Non-Preferred
Clopidogrel	ASA/dipyridamole
Brilinta®	ASA/omeprazole DR
Prasugrel*	Dipyridamole
	Vorapaxar
MOVEMENT DISORDERS	
Preferred	Non-Preferred
Austedo® *	Xenazine®
Tetrabenazine*	
Ingrezza® *	

* Added as “Preferred”

** Moved to “Non-Preferred”

5. Old Business

None

6. New Business

Lisa Correll presented new drugs to market and therapeutic classes for P&T Committee review.

Cheryl Anderson shared SCDHHS news and program updates. She welcomed Brandie Crider CPhT, Operations Manager of Pharmacy Services and Kim Bristow,

RPh, Assistant Director of Pharmacy Services to the SCDHHS pharmacy team. Effective November 1, 2022, Janet Giles accepted a position within the Office of Waivers.

Mercer is conducting the annual random survey of actual acquisition cost (AAC) on behalf of SCDHHS to ensure the AAC rates are fair, equitable, and reflective of actual drug ingredient cost for SC participating pharmacies. The Pharmacy Access Act has recently passed recognizing pharmacists as providers. Additional details will be furnished once the Joint Committee of the SC Board of Medical Examiners and the SC Board of Pharmacy publishes the final approved protocol for the Pharmacy Access Act.

7. Resolved Items

Classes for Re-Review

Acne Agents, Topical
Atypical Antipsychotics, Long Acting Injectables
2nd Generation Antipsychotics, Oral
Platelet Aggregation Inhibitors

Classes for Review

Movement Disorders

8. Closing Comments

The next meeting will be held Wednesday, February 1, 2023.

9. Adjournment

The meeting adjourned at 5:51 p.m.